28 Efficacy and Safety of Betibeglogene Autotemcel (beti-cel) Gene Therapy in 63 Patients with Transfusion-Dependent ß-Thalassemia (TDT): 7-Year Post-Infusion Follow-up of Phase 1/2 and Phase 3 Studies.

Transplantation and Cellular Therapy

Jennifer Schneiderman, Franco Locatelli, Alexis A. Thompson, Janet L. Kwiatkowski, John B. Porter, Suradej Hongeng, Andreas E. Kulozik, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, John E.J. Rasko, Evangelia Yannaki, Manfred Schmidt, Lin Du, Richard A. Colvin, Mark C. Walters. 28 Efficacy and Safety of Betibeglogene Autotemcel (beti-cel) Gene Therapy in 63 Patients with Transfusion-Dependent ß-Thalassemia (TDT): 7-Year Post-Infusion Follow-up of Phase 1/2 and Phase 3 Studies. Transplantation and Cellular Therapy. 2022 Mar 1; 28(3):s26-s27.

2022
https://researcherprofiles.org/profile/425025841

Jennifer Schneiderman, Franco Locatelli, Alexis A. Thompson, Janet L. Kwiatkowski, John B. Porter, Suradej Hongeng, Andreas E. Kulozik, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, John E.J. Rasko, Evangelia Yannaki, Manfred Schmidt, Lin Du, Richard A. Colvin, Mark C. Walters